Estuary Biotherapeutics raises $93M series a

◆ Amount

$93M

◆ Announced

16 Oct 2026

◆ Company

◆ Source

◆ The Round

Estuary Biotherapeutics raised $93M in series a funding, announced on 16 October 2026, led by RA Capital Management, with participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, National Kidney Foundation Innovation Fund, 4BIO Capital, GV. The round is tracked live by Fusion42 as part of the Raise fund database and the Scout startup database.

◆ About Estuary Biotherapeutics

Gene therapy company developing kidney-directed AAV delivery platform for autosomal dominant polycystic kidney disease (ADPKD). Estuary Biotherapeutics is based in United States and currently at series a stage, operating in Biotech.

◆ Investors

◆ Investing funds on Raise

• FGV Capital

◆ Market context

FGV Capital is profiled on Raise, Fusion42's database of venture funds — where each investor's thesis, cheque size and other tracked backings can be followed. This funding event is a citable node in Fusion42's market graph: it links Estuary Biotherapeutics's Scout profile to the funds behind the round and to related Wire analysis, and is refreshed from public announcements as the round is confirmed or extended. It is the same live market data Arthur reasons over when benchmarking a founder's own raise against what is closing in the market right now.

◆ Explore the market